- Sorrento Therapeutics Inc (NASDAQ:SRNE) announced the publication of a preprint entitled "Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta."
- Serum collected from omicron-specific mRNA vaccine immunized animals provided superior protection against the infection of omicron strain, including the BA.1, BA.1+R346K, and the more recent BA.2 sublineage.
- The data demonstrated that the newly designed mRNA vaccine could induce potent production of omicron-specific neutralization antibodies (nAbs) in vivo.
- Related: Sorrento's mRNA COVID-19 Vaccine Shows Efficacy In Preclinical Study.
- Even in animals previously vaccinated with the original WA1 spike mRNA, a single booster with omicron-specific mRNA still provided excellent protection against omicron infection.
- When immunized with a designer chimeric Delta RBD-Omicron mRNA vaccine, there was a significant increase in the nAb titer against the Delta variant and strong nAbs against the Omicron variants.
- Price Action: SRNE shares are up 0.19% at $2.63 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Sorrento's Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks